Non-Hodgkin Lymphoma | Specialty

The OncLive Non-Hodgkin Lymphoma condition center page is a comprehensive resource for clinical news and expert insights on various types of non-Hodgkin lymphoma, including diffuse large B-cell lymphoma, follicular lymphoma, chronic lymphocytic leukemia, and more. This page features news articles, interviews in written and video format, and podcasts that focus on unmet needs, treatment advances, and ongoing research in non-Hodgkin lymphoma.

Dr. Mehta-Shah on the Variations of the CHOP Regimen in PTCL

July 20th 2022

Neha Mehta-Shah, MD, MSCI, discusses variations of CHOP-based chemotherapy in peripheral T-cell lymphoma.

Mosunetuzumab Monotherapy Generates Promising Responses in Relapsed/Refractory Follicular Lymphoma

July 20th 2022

Single-agent mosunetuzumab produced a complete response rate that was greater than what has been observed with historical controls in patients with relapsed/refractory follicular lymphoma who had received at least 2 prior lines of therapy, meeting the primary end point of the expansion portion of the phase 1/2 GO29781 trial.

CB-010 Exhibits Impressive Early Efficacy in Relapsed/Refractory B-cell Non-Hodgkin Lymphoma

July 20th 2022

The CAR T-cell therapy CB-010 displayed promising preliminary efficacy and safety results in patients with relapsed/refractory B-cell non-Hodgkin lymphoma according to findings from the phase 1 ANTLER trial presented during the 2022 Pan Pacific Lymphoma Meeting.

Polatuzumab Vedotin Plus R-CHP Significantly Extends PFS in Untreated DLBCL

July 19th 2022

Polatuzumab vedotin, in combination with rituximab, cyclophosphamide, doxorubicin, and prednisone, induced a 27% reduction in relative risk for disease progression, relapse, or death for patients with newly diagnosed diffuse large B-cell lymphoma.

Pirtobrutinib Elicits 50% Response Rate in BTK-Pretreated MCL

July 19th 2022

Pirtobrutinib demonstrated potent antitumor activity and a low incidence of adverse effects in patients with BTK-pretreated and -naïve mantle cell lymphoma.

Zanubrutinib Represents Viable Treatment Option for Acalabrutinib-Intolerant B-cell Malignancies

July 19th 2022

Treatment with zanubrutinib maintained or improved response without an increase in acalabrutinib intolerance events in patients with previously treated B-cell malignancies.

CHOP-Based Combinations Represent Evolving Standard of Care in Frontline Treatment of PTCL

July 19th 2022

Neha Mehta-Shah, MD, MSCI, discusses frontline therapies in peripheral T-cell lymphoma, highlighting the current treatment landscape and the need to explore more treatment options in clinical trials.

BTK Inhibitor–Based Combinations May Improve the Efficacy of SOC Treatment in CNS Lymphoma

July 19th 2022

Avyakta Kallam, MBBS, discusses the benefits and shortcomings of the current standard of care in central nervous system lymphoma and expressed the importance of studying frontline targeted agents in this population.

Pirtobrutinib Demonstrates Encouraging Efficacy, Favorable Safety in Previously Treated CLL/SLL

July 14th 2022

Pirtobrutinib continued to produce promising responses in heavily pretreated patients with chronic lymphocytic leukemia or small lymphocytic lymphoma, irrespective of BTK C481 mutation status, reason for prior BTK inhibitor discontinuation, or other classes of previous therapy received.

Ibrutinib/Obinutuzumab Combo Elicits Durable Responses in Relapsed/Refractory CLL

July 13th 2022

Findings from a phase 1b trial showed that the addition of obinutuzumab to ibrutinib produced a complete response rate that compared favorably with what has historically been observed with ibrutinib monotherapy in patients with relapsed or refractory chronic lymphocytic leukemia.

Anbalcabtagene Autoleucel Elicits Meaningful Responses in Relapsed/Refractory LBCL

July 8th 2022

The CAR T-cell therapy anbalcabtagene autoleucel generated strong overall response rates in patients with relapsed/refractory large B-cell lymphoma.

Tisa-cel Adds a Potential New ‘Standard-of-Care’ in Third-Line Treatment of Follicular Lymphoma

July 6th 2022

Stephen J. Schuster, MD, discusses the implications of the FDA approval of tisagenlecleucel on the treatment strategy for relapsed/refractory follicular lymphoma and the next steps for tisa-cel.

Brexucabtagene Autoleucel Has Durable Efficacy in B-ALL, Irrespective of Age and Tumor Burden

July 4th 2022

Bijal Shah, MD, MS, discusses the long-term data from the ZUMA-3 trial of brexucabtagene autoleucel in patients with relapsed/refractory B-cell acute lymphoblastic leukemia and spotlighted additional areas ripe for further exploration.

FDA Approval Sought for Subcutaneous Epcoritamab for Relapsed/Refractory LBCL

July 1st 2022

Genmab A/S shared plans to submit a biologics license application to the FDA seeking the approval of subcutaneous epcoritamab for the treatment of patients with relapsed or refractory large B-cell lymphoma in the second half of 2022.

Orelabrutinib/Sintilimab Combo Induces Rapid Responses in Peripheral CNS Lymphoma

June 29th 2022

The addition of orelabrutinib to sintilimab demonstrated good efficacy with a rapid time to response in patients with relapsed/refractory primary central nervous system lymphoma.

Dr. Ghosh on the Safety Data Seen With Liso-cel in LBCL

June 27th 2022

Nilanjan Ghosh, MD, PhD, discusses the low toxicity levels with lisocabtagene maraleucel that were seen in patients with relapsed/refractory large B cell lymphoma in the phase 3 TRANSFORM trial.

FDA Grants Orphan Drug Designation to MB-106 for Waldenström Macroglobulinemia

June 22nd 2022

The FDA has granted an orphan drug designation to the CD20-targeted autologous CAR T-cell therapy, MB-106, for use as a potential therapeutic option in patients with Waldenström macroglobulinemia.

Ibrutinib Plus Bendamustine and Rituximab Prolongs PFS Benefit in Newly Diagnosed MCL

June 21st 2022

Michael Wang, MD, discusses the innovative design of the SHINE trial, notes the importance of developing improved treatments for older patient populations, and highlights significant progression-free survival and safety data from the study.

Nemtabrutinib Generates Responses, Displays Manageable Safety in CLL/SLL

June 20th 2022

Nemtabrutinib, a potent, non-covalent BTK inhibitor, continued to demonstrate antitumor activity with an acceptable safety profile in patients with chronic lymphocytic leukemia and small lymphocytic lymphoma.

European Medicines Agency Validates Type II Variation Application for Liso-cel in Second-line LBCL

June 20th 2022

The European Medicines Agency has verified its type II variation application to extend the indication for lisocabtagene maraleucel to include the treatment of adult patients with diffuse large B-cell lymphoma, high grade B-cell lymphoma, primary mediastinal large B-cell lymphoma, and grade 3B follicular lymphoma, who are refractory or have relapsed within 12 months of initial therapy and are candidates for hematopoietic stem cell transplant.